{
    "info": {
        "nct_id": "NCT04601402",
        "official_title": "A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination With Avelumab in Patients With Advanced Solid Tumors Who Have Progressed During or After Treatment With Anti-PD-(L)1 Therapy",
        "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate organ functions as defined in the protocol\n* Negative childbearing potential\n* Have ability to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities\n* Patients with diseases for which no curative therapies are available, and who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)\n* Disease progression on anti-PD-(L)1 based therapy (as monotherapy or combination therapy) and must meet criteria for acquired resistance as defined in the protocol\n* Patients who have completely recovered from any clinically significant AEs that occurred during prior immunotherapy\n* Estimated life expectancy of at least 3 months\n* Objective evidence of disease progression at baseline (Dose Escalation)\n* Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic NSCLC, SCCHN, and UC (Dose Expansion)\n* Measurable disease as per RECIST v1.1 defined as at least 1 lesion (Dose Expansion)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Have experienced primary resistance to anti-PD-(L)1 based therapy\n* Has experienced a toxicity that led to permanent discontinuation of prior anti-PD-(L)1 based therapy or other immunotherapies\n* Has active autoimmune disease that has required systemic treatment in the past 2 years\n* Current use of immunosuppressive medication at time of study entry\n* Have an active infection requiring antibiotics, antifungal or antiviral agents or have received a course of antibiotics within the previous 4 weeks of starting study treatment\n* Has received a live vaccine within 4 weeks of starting of study treatment\n* Known history of, or any evidence of active, non-infectious pneumonitis\n* Prior solid organ or allogeneic stem cell transplantation\n* Has had any investigational or anti-tumor treatment within 4 weeks or 5 half-life periods of starting study treatment, had any major surgeries within 4 weeks of starting study treatment\n* Has received proton pump inhibitors (PPIs) within 2 weeks prior to dosing study treatments\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has clinically significant (i.e., active) cardiovascular disease\n* Has known history of uncontrolled intercurrent illness\n* Has any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have adequate organ functions as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "Have adequate organ functions",
                    "criterion": "organ functions",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have ability to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities",
            "criterions": [
                {
                    "exact_snippets": "Have ability to swallow and retain oral medication",
                    "criterion": "ability to swallow and retain oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no clinically significant gastrointestinal abnormalities",
                    "criterion": "clinically significant gastrointestinal abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with diseases for which no curative therapies are available, and who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)",
            "criterions": [
                {
                    "exact_snippets": "diseases for which no curative therapies are available",
                    "criterion": "disease with no available curative therapies",
                    "requirements": [
                        {
                            "requirement_type": "curative therapy availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "progressed on at least two lines of approved therapy for their histological subtypes",
                    "criterion": "progression on approved therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number of approved therapy lines progressed on",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)",
                    "criterion": "prior anti-PD-1 or anti-PD-L1 based therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy includes anti-PD-1 or anti-PD-L1",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as per RECIST v1.1 defined as at least 1 lesion (Dose Expansion)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as per RECIST v1.1 defined as at least 1 lesion (Dose Expansion)",
                    "criterion": "measurable disease (per RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Objective evidence of disease progression at baseline (Dose Escalation)",
            "criterions": [
                {
                    "exact_snippets": "Objective evidence of disease progression at baseline (Dose Escalation)",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "evidence type",
                            "expected_value": "objective"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at baseline"
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "Dose Escalation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated life expectancy of at least 3 months",
            "criterions": [
                {
                    "exact_snippets": "Estimated life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic NSCLC, SCCHN, and UC (Dose Expansion)",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable",
                    "criterion": "resectability of disease",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced, or metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "NSCLC, SCCHN, and UC",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "NSCLC",
                                "SCCHN",
                                "UC"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease progression on anti-PD-(L)1 based therapy (as monotherapy or combination therapy) and must meet criteria for acquired resistance as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "Disease progression on anti-PD-(L)1 based therapy (as monotherapy or combination therapy)",
                    "criterion": "disease progression on anti-PD-(L)1 based therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "progressed"
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "anti-PD-1",
                                "anti-PD-L1"
                            ]
                        },
                        {
                            "requirement_type": "therapy_regimen",
                            "expected_value": [
                                "monotherapy",
                                "combination therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must meet criteria for acquired resistance as defined in the protocol",
                    "criterion": "acquired resistance",
                    "requirements": [
                        {
                            "requirement_type": "meets_protocol_definition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have completely recovered from any clinically significant AEs that occurred during prior immunotherapy",
            "criterions": [
                {
                    "exact_snippets": "completely recovered from any clinically significant AEs that occurred during prior immunotherapy",
                    "criterion": "clinically significant adverse events (AEs) during prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "completely recovered"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has clinically significant (i.e., active) cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "clinically significant (i.e., active) cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an active infection requiring antibiotics, antifungal or antiviral agents or have received a course of antibiotics within the previous 4 weeks of starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "Have an active infection requiring antibiotics, antifungal or antiviral agents",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires antimicrobial therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have received a course of antibiotics within the previous 4 weeks of starting study treatment",
                    "criterion": "antibiotic use within previous 4 weeks",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior solid organ or allogeneic stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior solid organ ... transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allogeneic stem cell transplantation",
                    "criterion": "allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 4 weeks of starting of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 4 weeks of starting of study treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known history of uncontrolled intercurrent illness",
            "criterions": [
                {
                    "exact_snippets": "Has known history of uncontrolled intercurrent illness",
                    "criterion": "uncontrolled intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current use of immunosuppressive medication at time of study entry",
            "criterions": [
                {
                    "exact_snippets": "Current use of immunosuppressive medication at time of study entry",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at time of study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active autoimmune disease that has required systemic treatment in the past 2 years",
            "criterions": [
                {
                    "exact_snippets": "Has active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in the past 2 years",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of, or any evidence of active, non-infectious pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Known history of ... active, non-infectious pneumonitis",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "any psychiatric condition that would prohibit the understanding or rendering of informed consent",
                    "criterion": "psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "impact on understanding or rendering of informed consent",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any psychiatric condition ... that would limit compliance with study requirements",
                    "criterion": "psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance with study requirements",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have experienced primary resistance to anti-PD-(L)1 based therapy",
            "criterions": [
                {
                    "exact_snippets": "Have experienced primary resistance to anti-PD-(L)1 based therapy",
                    "criterion": "primary resistance to anti-PD-(L)1 based therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": "primary resistance to anti-PD-(L)1 based therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Has known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "and/or carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received proton pump inhibitors (PPIs) within 2 weeks prior to dosing study treatments",
            "criterions": [
                {
                    "exact_snippets": "Has received proton pump inhibitors (PPIs) within 2 weeks prior to dosing study treatments",
                    "criterion": "proton pump inhibitor (PPI) use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to dosing study treatments"
                            }
                        },
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has experienced a toxicity that led to permanent discontinuation of prior anti-PD-(L)1 based therapy or other immunotherapies",
            "criterions": [
                {
                    "exact_snippets": "Has experienced a toxicity that led to permanent discontinuation of prior anti-PD-(L)1 based therapy or other immunotherapies",
                    "criterion": "toxicity from prior anti-PD-(L)1 based therapy or other immunotherapies",
                    "requirements": [
                        {
                            "requirement_type": "history of toxicity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "toxicity outcome",
                            "expected_value": "permanent discontinuation of prior anti-PD-(L)1 based therapy or other immunotherapies"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had any investigational or anti-tumor treatment within 4 weeks or 5 half-life periods of starting study treatment, had any major surgeries within 4 weeks of starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "Has had any investigational or anti-tumor treatment within 4 weeks or 5 half-life periods of starting study treatment",
                    "criterion": "prior investigational or anti-tumor treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-life periods"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "had any major surgeries within 4 weeks of starting study treatment",
                    "criterion": "prior major surgeries",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}